Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | CBS | P35520 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18074854 | 0.71 | TSHR (0.33) | PTGDRPTGDR2TSHRCTHCBS | |
| SCHEMBL31213026 | 0.71 | CYP1A2 (0.38) | PTGDRPTGDR2TSHRCTHCBS | |
| SCHEMBL31213025 | 0.70 | CYP1A2 (0.41) | PTGDRPTGDR2TSHRCTHCBS | |
| SCHEMBL21570221 | 0.67 | HSD17B10 (0.31) | TSHRCTHCBSTHPOFFAR3 | |
| SCHEMBL25070961 | 0.65 | CYP2C19 (0.38) | TSHRFFAR3 | |
| SCHEMBL7175558 | 0.64 | CYP2C19 (0.33) | PTGDRPTGDR2TSHRCTHCBS | |
| SCHEMBL27009186 | 0.64 | NPSR1 (0.35) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL20721979 | 0.64 | TSHR (0.35) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL23603986 | 0.62 | ADORA3 (0.35) | TSHRFFAR3FFAR4 | |
| SCHEMBL21810913 | 0.62 | TSHR (0.33) | PTGDRPTGDR2TSHRCTHCBS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262658-A1 | PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS | ZOPPAS MATTEO | 2011-10-27 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| EP-1954287-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | PTGDR 4746/4885PTGDR2 4737/4885TSHR 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.